Table 5 FDA-approved therapeutic drugs for prostate cancers
Drug (brand name) | Sponsor | Properties | Indication | Approval date | Review |
|---|---|---|---|---|---|
Bicalutamide (Casodex) | Ani pharms | AR antagonist | Advanced prostate cancer | 10/04/1995 | S |
Nilutamide (Nilandron) | Concordia | AR antagonist | Metastatic prostate cancer | 09/19/1996 | S |
Enzalutamide (Xtandi) | Astellas | AR antagonist | mCRPC | 08/31/2012 | P |
Apalutamide (Erleada) | Janssen | AR antagonist | Prostate cancer | 02/14/2018 | P |
Darolutamide (Nubeqa) | Bayer | AR antagonist | Prostate cancer | 7/30/2019 | P |
Triptorelin pamoate (Trelstar) | Verity | GnRH agonist | Advanced prostate cancer | 06/15/2000 | S |
Abarelix (Plenaxis) | Speciality | GnRH receptor antagonist | Advanced prostate cancer | 11/25/2003 | P |
Degarelix acetate (Firmagon) | Ferring | GnRH receptor antagonist | Advanced prostate cancer | 12/24/2008 | S |
Relugolix (Orgovyx) | Myovant | GnRH receptor antagonist | Prostate cancer | 12/18/2020 | P |
Cabazitaxel (Jevtana kit) | Sanofi | Microtubule-stabilizing agent | Prostate cancer | 06/17/2010 | P |
Abiraterone acetate (Zytiga) | Janssen | CYP17A1 inhibitor | mCRPC | 04/28/2011 | P |
Radium RA 223 dichloride (Xofigo) | Bayer | α-particle-emitting radiopharmaceutical | mCRPC | 05/15/2013 | P |